InnovAge (INNV) Projected to Post Quarterly Earnings on Tuesday

InnovAge (NASDAQ:INNV) is expected to announce its Q2 2026 results after the market closes on Tuesday, February 3rd. Analysts expect InnovAge to post earnings of $0.04 per share and revenue of $228.30 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, February 3, 2026 at 5:00 PM ET.

InnovAge (NASDAQ:INNV) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.05. The firm had revenue of $236.11 million during the quarter, compared to analysts’ expectations of $226.64 million. InnovAge had a negative return on equity of 7.02% and a negative net margin of 1.96%. On average, analysts expect InnovAge to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

InnovAge Stock Up 3.6%

Shares of NASDAQ INNV opened at $6.04 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.25. The firm’s 50-day simple moving average is $5.45 and its 200 day simple moving average is $4.80. InnovAge has a 12-month low of $2.60 and a 12-month high of $6.26. The company has a market cap of $819.51 million, a price-to-earnings ratio of -46.46 and a beta of 0.57.

Insider Buying and Selling at InnovAge

In other news, COO Michael Anthony Scarbrough sold 33,000 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $4.90, for a total value of $161,700.00. Following the sale, the chief operating officer directly owned 119,617 shares of the company’s stock, valued at approximately $586,123.30. This represents a 21.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On InnovAge

Several hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its holdings in InnovAge by 26.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 15,993 shares of the company’s stock valued at $83,000 after buying an additional 3,305 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of InnovAge by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,124,321 shares of the company’s stock valued at $5,801,000 after purchasing an additional 4,239 shares during the last quarter. Bank of America Corp DE increased its position in InnovAge by 42.4% during the 4th quarter. Bank of America Corp DE now owns 19,945 shares of the company’s stock worth $78,000 after purchasing an additional 5,936 shares in the last quarter. Jane Street Group LLC increased its holdings in InnovAge by 18.9% in the 1st quarter. Jane Street Group LLC now owns 46,827 shares of the company’s stock worth $140,000 after purchasing an additional 7,429 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in InnovAge by 3.0% in the 2nd quarter. Geode Capital Management LLC now owns 554,880 shares of the company’s stock valued at $2,048,000 after acquiring an additional 16,205 shares during the period. 12.26% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on INNV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of InnovAge in a research report on Thursday. Wall Street Zen upgraded shares of InnovAge to a “strong-buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell” and a consensus price target of $5.00.

InnovAge Company Profile

InnovAge Holdings, Inc (NASDAQ:INNV) is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals who are eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services and long-term care—delivered primarily in participants’ homes and community-based centers. InnovAge’s approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.

The company’s core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments.